Carole L. Marcus, M.B vardenafilgen.com ., B.Ch. Moore, Ph.D., Carol L. Rosen, M.D., Bruno Giordani, Ph.D., Susan L. Garetz, M.D., H. Gerry Taylor, Ph.D., Ron B. Mitchell, M.D., Raouf Amin, M.D., Eliot S. Katz, M.D., Raanan Arens, M.D., Shalini Paruthi, M.D., Hiren Muzumdar, M.D., David Gozal, M.D., Nina Hattiangadi Thomas, Ph.D., Janice Ware, Ph.D., Dean Beebe, Ph.D., Karen Snyder, M.S., Lisa Elden, M.D., Robert C. Sprecher, M.D., Paul Willging, M.D., Dwight Jones, M.D., John P. Bent, M.D., Timothy Hoban, M.D., Ronald D. Chervin, M.D., Susan S. Ellenberg, Ph.D., and Susan Redline, M.D., M.P.H. For
Hossein-Ardeschir Ghofrani, M.D.D., Friedrich Grimminger, M.D.D., Marc Humbert, M.D., Zhi-Cheng Jing, M.D., Anne M. Keogh, M.D., David Langleben, M.D., Michael Ochan Kilama, M.D., Arno Fritsch, Ph.D., Dieter Neuser, M.D., and Lewis J. Rubin, M.D. For the PATENT-1 Study Group: Riociguat for the Treatment of Pulmonary Arterial Hypertension Pulmonary arterial hypertension is definitely a life-threatening disease that’s characterized by increased pulmonary vascular resistance owing to progressive vascular remodeling, that may result in right heart failure and death ultimately.1,2 Current remedies include phosphodiesterase type 5 inhibitors, prostanoids, and endothelin-receptor antagonists.1 However, mortality continues to be high despite treatment,3 and there is a considerable unmet medical want in the administration of this disorder.